Christopher A Reid

Title: Innovations by Christopher A Reid in Gene Therapy

Introduction

Christopher A Reid is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of gene therapy, holding 2 patents that focus on innovative approaches to treating heart diseases. His work is pivotal in advancing therapeutic techniques that can potentially improve patient outcomes.

Latest Patents

Reid's latest patents include "Optimized expression cassettes for gene therapy" and "Adeno-associated virus with engineered capsid." The first patent provides cardiac-specific expression cassettes that comprise a polynucleotide sequence encoding a gene product for heart disease therapy. This expression cassette is operably linked to a cardiac-specific promoter and may include a cardiac-specific enhancer. Additionally, it discusses recombinant adeno-associated virus (rAAV) virions that contain a therapeutic gene product, such as the dwarf open reading frame (DWORF) polypeptide, linked to a promoter and flanked by inverted terminal repeats. The second patent focuses on rAAV virions with engineered capsid proteins that enhance transduction efficiency in cardiac cells, thereby increasing cell-type selectivity and other beneficial properties.

Career Highlights

Christopher A Reid is currently associated with Tenaya Therapeutics, Inc., where he continues to innovate in the field of gene therapy. His work is characterized by a commitment to developing effective treatments for heart diseases, leveraging advanced genetic engineering techniques.

Collaborations

Reid collaborates with Huanyu Zhou, contributing to the collective expertise and innovation within their research endeavors.

Conclusion

Christopher A Reid's contributions to gene therapy through his patents and work at Tenaya Therapeutics, Inc. highlight his role as a leading inventor in the field. His innovative approaches have the potential to significantly impact the treatment of heart diseases.